| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite Microbial Metabolite
Endogenous Metabolite; substrate for inosine-5′-monophosphate dehydrogenase (IMPDH). IMP is converted to XMP by IMPDH, the rate-limiting step in de novo guanine nucleotide biosynthesis. Precursor to both ATP and GTP, involved in purine metabolism and energy homeostasis. |
|---|---|
| ln Vitro |
As an endogenous metabolite, IMP is a key intermediate in purine metabolism, substrate for IMPDH (converts IMP to XMP, rate-limiting for guanine nucleotide synthesis). First nucleotide formed in de novo purine synthesis, precursor to ATP and GTP. Used as a flavor enhancer (disodium inosinate, E631) in processed foods. Studied for potential health benefits including improving athletic performance and reducing inflammation.
|
| ln Vivo |
IMP is an endogenous intermediate in purine metabolism. Studied for potential health benefits (athletic performance, reducing inflammation). Widely consumed as a flavor enhancer (GRAS). In animal models, may influence purine nucleotide pools, energy metabolism, immune function, and uric acid levels (precursor for uric acid via xanthine oxidase).
|
| Enzyme Assay |
(1) IMPDH enzyme assay: incubate recombinant human IMPDH2 (1-10 ng) with IMP (100-500 uM), NAD+ (1-2 mM) in 50 mM Tris-HCl pH8.0, 100 mM KCl, 1 mM DTT. Monitor NADH production at 340 nm or XMP formation by HPLC at 290 nm. (2) To test inhibitors, add test compounds and calculate IC50.
|
| Cell Assay |
(1) Seed cancer cells or hepatocytes in 96-well plates (5,000-10,000/well). (2) For purine metabolism: treat with IMP (0.1-10 mM) for 6-24 h. (3) Extract nucleotides with 80% ice-cold methanol, analyze by LC-MS/MS for IMP, AMP, ADP, ATP, GMP, GDP, GTP. (4) Cell viability: treat with IMP 0.1-50 mM for 48-72 h, MTT/CCK-8; IMP is non-toxic up to 10 mM. (5) For IMPDH activity in cell lysates: lyse cells, add IMP (1 mM), NAD+ (2 mM), monitor NADH at 340 nm.
|
| Animal Protocol |
(1) For PK: use male Sprague-Dawley rats (200-250 g) or C57BL/6 mice (20-25 g). (2) Administer IMP disodium salt by oral gavage (50-200 mg/kg) or IV (10-50 mg/kg) in sterile saline/PBS pH7.0-7.4. (3) Collect blood at 0,0.25,0.5,1,2,4,8,12,24 h, plasma deproteinized with 3 vol ice-cold methanol. (4) Analyze IMP and metabolites (inosine, hypoxanthine, uric acid) by LC-MS/MS. (5) Calculate PK parameters. (6) For tissue distribution: collect liver, kidney, small intestine, muscle at 0.5-4 h, homogenize, extract, analyze. (7) For excretion: collect 24-h urine in metabolic cages.
|
| ADME/Pharmacokinetics |
Soluble in water (≥50 mg/mL) and phosphate buffer pH7.0. For cell culture, dissolve directly or prepare 50-100 mM stock in water, filter sterilize. For in vivo, dissolve in sterile saline or PBS at 10-50 mg/mL. Storage: powder at -20degC for 3 years, protect from moisture; solution at -20degC for 6 months, -80degC for 1 year. Hygroscopic; store tightly sealed.
|
| Toxicity/Toxicokinetics |
IMP is an endogenous nucleotide, non-toxic at physiological concentrations. In vitro: CCK-8 on HEK293 cells with IMP up to 50 mM for 48 h shows IC50 >100 mM. In vivo: oral LD50 in rats >10,000 mg/kg; IV LD50 in mice ~2,000-5,000 mg/kg. As food additive (E631) at up to 0.5 g/kg food, GRAS. Very high doses (>5 g/day) may cause mild GI upset or increased serum uric acid. No teratogenic or carcinogenic effects.
|
| Additional Infomation |
IMP (disodium inosinate) is a naturally occurring purine nucleotide and key intermediate in de novo purine biosynthesis, first nucleotide formed, branching point for AMP and GMP synthesis. Widely used as flavor enhancer (E631), often with disodium guanylate (E627) and MSG for umami taste. In research, used as substrate to study IMPDH, an important target for immunosuppressive (mycophenolic acid) and anticancer (ribavirin, tiazofurin) drugs. Not FDA-approved as a drug; strictly for research and food additive use.
|
| CAS # |
352195-40-5
|
|---|---|
| Related CAS # |
Inosinic acid;131-99-7
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
175ºC
|
| LogP |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~250 mg/mL (~637.48 mM)
DMSO :~1 mg/mL (~2.55 mM (<80°C)) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (127.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
